Cover Image

Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy

BackgroundBeta blockers improve survival in patients with chronic systolic heart failure (CHF). Whether physicians should aim for target dose, target heart rate (HR), or both is still under debate.Methods and ResultsWe identified 1,669 patients with systolic CHF due to ischemic heart disease or idio...

Full description

Saved in:
Bibliographic Details
Main Authors: Corletto, Anna (Author) , Fröhlich, Hanna (Author) , Täger, Tobias (Author) , Hochadel, Matthias (Author) , Zahn, Ralf (Author) , Kilkowski, Caroline (Author) , Winkler, Ralph (Author) , Senges, Jochen (Author) , Katus, Hugo (Author) , Frankenstein, Lutz (Author)
Format: Article (Journal)
Language:English
Published: [November 2018]
In: Clinical research in cardiology
Year: 2018, Volume: 107, Issue: 11, Pages: 1040-1049
ISSN:1861-0692
DOI:10.1007/s00392-018-1277-4
Online Access:Verlag, Volltext: https://doi.org/10.1007/s00392-018-1277-4
Get full text
Author Notes:Anna Corletto, Hanna Fröhlich, Tobias Täger, Matthias Hochadel, Ralf Zahn, Caroline Kilkowski, Ralph Winkler, Jochen Senges, Hugo A. Katus, Lutz Frankenstein
Description
Summary:BackgroundBeta blockers improve survival in patients with chronic systolic heart failure (CHF). Whether physicians should aim for target dose, target heart rate (HR), or both is still under debate.Methods and ResultsWe identified 1,669 patients with systolic CHF due to ischemic heart disease or idiopathic dilated cardiomyopathy from the University Hospital Heidelberg and the Clinic of Ludwigshafen, Germany. All patients were treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker and had a history of CHF known for at least 6 months. Target dose was defined as treatment with ≥ 95% of the respective published guideline-recommended dose. Target HR was defined as 51-69 bpm. All-cause mortality during the median follow-up of 42.8 months was analysed with respect to beta blocker dosing and resting HR. 201 (12%) patients met the dose target (group A), 285 (17.1%) met the HR target (group B), 627 (37.6%) met no target (group C), and 556 (33.3%) did not receive beta blockers (Group D). 5-year mortality was 23.7, 22.7, 37.6, and 55.6% for group A, B, C, and D, respectively (p < 0.001). Survival for group A patients with a HR ≥ 70 bpm was 28.8% but 14.8% if HR was 50-70 bpm (p = 0.054).ConclusionsAchieving guidelines recommended beta blocker dose or to HR control has a similar positive impact on survival. When on target dose, supplemental HR control additionally improves survival.
Item Description:Published online: 17 May 2018
Gesehen am 28.06.2019
Physical Description:Online Resource
ISSN:1861-0692
DOI:10.1007/s00392-018-1277-4

Similar Items